Literature DB >> 1907623

Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets.

D Gullo1, A M Rabuazzo, M Vetri, C Gatta, C Vinci, M Buscema, R Vigneri, F Purrello.   

Abstract

We investigated the effect of 24 h exposure to 100 nmol/l glibenclamide on insulin secretion in isolated rat pancreatic islets. The insulin content was similar in control islets and in islets preincubated with 100 nmol/l glibenclamide for 24 h. In islets preexposed to glibenclamide: 1) the subsequent response to a maximal glibenclamide stimulatory concentration (10 mumol/l, 1 h at 37 C) was greatly reduced in comparison to control islets (0.69 +/- 0.20% vs 2.16 +/- 0.41%; mean +/- SE; n = 14; p less than 0.001); 2) the response to 100 mumol/l tolbutamide stimulation was also reduced (0.55 +/- 0.15% vs 2.38 +/- 0.44%; n = 8; p less than 0.001); 3) the response to 16.7 mmo/l glucose, both in the presence or in the absence of 1 mmol/l IBMX, a phosphodiesterase inhibitor, was also diminished by about 50% (1.79 +/- 0.39% vs. 3.22 +/- 0.42%; n = 14, p less than 0.001). In glibenclamide pretreated islets, blunted responses to stimuli were confirmed also by dynamic studies using a perifusion system. The effect of glibenclamide preincubation was fully reversible: when islets cultured in the presence of glibenclamide were transferred to a glibenclamide-free medium for further 24 h, insulin release in response to glibenclamide stimulation returned to control values. We conclude that prolonged exposure of rat pancreatic islets to glibenclamide induces a reversible desensitization to a variety of metabolic stimuli. The inhibition by prolonged glibenclamide exposure of a common pathway in the mechanism of insulin release is one possible explanation for these results.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907623     DOI: 10.1007/BF03346813

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.

Authors:  B L Wajchenberg; M Nery; C E Leme; A A Silveira; P Fioratti; O A Germek
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

2.  Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.

Authors:  R A DeFronzo; D C Simonson
Journal:  Diabetes Care       Date:  1984 May-Jun       Impact factor: 19.112

3.  Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects.

Authors:  J P Palmer; J W Benson; R M Walter; J W Ensinck
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

4.  Glucose-induced insulin release depends on functional cooperation between islet cells.

Authors:  D Pipeleers; P I in't Veld; E Maes; M Van De Winkel
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

5.  An inhibitory effect of tolbutamide and glibenclamide (glyburide) on the pancreatic islets of normal animals.

Authors:  J C Dunbar; P P Foà
Journal:  Diabetologia       Date:  1974-02       Impact factor: 10.122

6.  Characteristics of desensitization of insulin secretion in fully in vitro systems.

Authors:  J L Bolaffi; L Bruno; A Heldt; G M Grodsky
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

7.  Interaction of sulfonylureas with pancreatic beta-cells. A study with glyburide.

Authors:  F K Gorus; F C Schuit; P A In't Veld; W Gepts; D G Pipeleers
Journal:  Diabetes       Date:  1988-08       Impact factor: 9.461

8.  Insulin responses to nonglucose stimuli in non-insulin-dependent diabetes mellitus during a tolbutamide infusion.

Authors:  M A Pfeifer; J B Halter; J C Beard; R Judzewitsch; D Porte
Journal:  Diabetes       Date:  1982-02       Impact factor: 9.461

9.  Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.

Authors:  J P Hosker; M A Burnett; E G Davies; E A Harris; R C Turner
Journal:  Diabetologia       Date:  1985-11       Impact factor: 10.122

10.  Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment.

Authors:  L Groop; P H Groop; S Stenman; C Saloranta; K J Tötterman; F Fyhrquist; A Melander
Journal:  Diabetes Care       Date:  1987 Nov-Dec       Impact factor: 19.112

View more
  5 in total

1.  Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.

Authors:  N H McClenaghan; A J Ball; P R Flatt
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

2.  Chronic stimulation induces adaptive potassium channel activity that restores calcium oscillations in pancreatic islets in vitro.

Authors:  Nathan C Law; Isabella Marinelli; Richard Bertram; Kathryn L Corbin; Cara Schildmeyer; Craig S Nunemaker
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-02-18       Impact factor: 4.310

3.  Drugs acting on SUR1 to treat CNS ischemia and trauma.

Authors:  J Marc Simard; S Kyoon Woo; Sergei Bhatta; Volodymyr Gerzanich
Journal:  Curr Opin Pharmacol       Date:  2007-11-26       Impact factor: 5.547

4.  Sulfonylurea receptor 1 mutations that cause opposite insulin secretion defects with chemical chaperone exposure.

Authors:  Emily B Pratt; Fei-Fei Yan; Joel W Gay; Charles A Stanley; Show-Ling Shyng
Journal:  J Biol Chem       Date:  2009-01-16       Impact factor: 5.157

5.  Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.

Authors:  Maria Sara Remedi; Colin G Nichols
Journal:  PLoS Med       Date:  2008-10-28       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.